After a years-long slump, Massachusetts biopharma sector has come roaring back in 2026

Young startups miss out on biotech venture funding rebound, MassBio says

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”